In this video, Dean Fennell, PhD, FRCP, of the University of Leicester, Leicester, UK, discusses upcoming therapeutic targets for mesothelioma and sarcomatoid carcinoma. Speaking at the 2018 European Lung Cancer Congress (ELCC) in Geneva, Switzerland, Prof. Fennell talks about the drugs bevacizumab and nintedanib for targeting angiogenesis, immunotherapeutic treatments including nivolumab, pembrolizumab and ipilimumab, and also potential targets for genetic therapy such as the ASS1 protein and the BAP1 gene.
Therapeutic targets for mesothelioma and sarcomatoid carcinoma
